Marcus Urey, MD
Advanced Heart Failure and Transplant Cardiology · San Diego, CANPI 1972820058
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Alnylam Pharmaceuticals Inc. at 38.8% of the total. Among advanced heart failure and transplant cardiology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 403 payments — averaging $846.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$132K
- AstraZeneca$84K
- Bridgebio Pharma, Inc.$44K
- Pfizer$42K
- Akcea Therapeutics, Inc.$19K
- Edwards Lifesciences$13K
- plus $8K from 11 others
Across 47 payments — averaging $12,255 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ionis Pharmaceuticals, Inc.$343K
- E.r. Squibb & Sons, L.L.C.$187K
- Alnylam Pharmaceuticals Inc.$28K
- AstraZeneca$17K
Across 2 payments — averaging $35,000 each. An ownership or investment interest held by the physician or an immediate family member.
- Vektor Medical Inc.$70K
What the payments were for
- Consulting fees$80,45124%
- Speaking & faculty fees$203,19060%
- Travel & lodging$43,73413%
- Food & beverage$13,5624%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 166 | $132,390 |
| AstraZeneca | 59 | $83,526 |
| Bridgebio Pharma, Inc. | 22 | $44,005 |
| Pfizer | 35 | $41,510 |
| Akcea Therapeutics, Inc. | 30 | $18,726 |
| Edwards Lifesciences | 16 | $13,203 |
| Abiomed | 32 | $3,923 |
| Abbott | 28 | $2,477 |
| Medtronic | 4 | $345 |
| Boston Scientific | 4 | $299 |
| Paragonix Technologies, Inc. | 1 | $163 |
| Boehringer Ingelheim | 1 | $124 |
| Cvrx, Inc. | 1 | $101 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $66 |
| Endotronix, Inc. | 1 | $50 |
| Scpharmaceuticals Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WAINUA$67,686
- ONPATTRO$62,926
- AMVUTTRA$43,928
- Attruby$43,795
- VYNDAQEL$30,698
- TEGSEDI$13,177
- VYNDAMAX$7,893
- Impella$2,357
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$756
- CARDIOMEMS$313
- 2ND GEN CENTRIMAG PRIMARY CONSOLE$258
- HeartMate$179
- SherpaPak$163
- LIVERguard$163
- LUNGguard$163
- BaroGuard$163
- PancreasPak$163
- HeartWare HVAD$146
- HeartMate 3 Left Ventricular Dev$138
- CardioMEMS HF System$138
How this compares
$340,945 in reported general payments places this provider in the 95th percentile of 111 advanced heart failure and transplant cardiology providers in California.
See all advanced heart failure and transplant cardiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 353 | $8,549,919 |
| VyndaqelTafamidis Meglumine | 43 | $872,902 |
| WainuaEplontersen Sodium | 12 | $429,579 |
| JardianceEmpagliflozin | 336 | $338,714 |
| ArcalystRilonacept | 13 | $304,430 |
| EntrestoSacubitril/Valsartan | 139 | $186,009 |
| EliquisApixaban | 173 | $149,726 |
| FarxigaDapagliflozin Propanediol | 115 | $100,687 |
| TrulicityDulaglutide | 75 | $74,748 |
| Sirolimus | 193 | $61,329 |
| Envarsus XrTacrolimus | 86 | $47,680 |
| VeltassaPatiromer Calcium Sorbitex | 30 | $34,490 |
| XareltoRivaroxaban | 17 | $22,516 |
| Everolimus | 11 | $17,119 |
| OzempicSemaglutide | 19 | $16,779 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $41,510 | $9,572,547569 claims |
| AstraZenecaWainua, Farxiga | $83,526 | $530,266127 claims |
| Boehringer IngelheimJardiance | $124 | $338,714336 claims |
| Johnson & JohnsonXarelto | $19 | $22,51617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 111 advanced heart failure and transplant cardiology providers in California.
Other advanced heart failure and transplant cardiology in San Diego
- Hirsch MehtaSan Diego$494K
- Barry GreenbergSan Diego$270K
- Brian JaskiSan Diego$235K
- Ajay SrivastavaSan Diego$203K
- Jorge Silva EncisoSan Diego$164K
- Burhan MohamedaliSan Diego$154K
- Hao TranSan Diego$147K
- Justin ParizoSan Diego$24K
- Eric AdlerSan Diego$24K
- Peter HoaglandSan Diego$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.